Meloxicam Stada

Meloxicam, the active ingredient in Meloxicam Stada, is a nonsteroidal anti-inflammatory drug (NSAID) presented as an oral tablet for oral use. It is employed to relieve pain and inflammation associated with osteoarthritis, rheumatoid arthritis, and acute musculoskeletal conditions in adult patients.

GNH USA supplies Meloxicam Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality, regulatory compliance and reliable logistics for global healthcare providers through validated manufacturing processes and continuous product monitoring across multiple regions.

Meloxicam is indicated for conditions involving inflammatory joint disease and acute musculoskeletal pain, acting through COX‑2 inhibition to reduce inflammation. - Osteoarthritis: reduces joint pain and swelling, improving mobility. - Rheumatoid arthritis: alleviates chronic inflammation and joint damage progression. - Acute musculoskeletal pain: provides rapid relief of pain and inflammation following injury or strain.

Adverse reactions to meloxicam may vary in frequency and severity.

Common Side Effects: - Gastrointestinal discomfort: nausea, dyspepsia or abdominal pain. - Headache: mild to moderate intensity. - Dizziness: transient sensation of light‑headedness. - Edema: peripheral swelling, especially of the ankles. - Skin rash: mild erythema or pruritus.

Serious or Rare Side Effects: - Gastrointestinal ulceration or bleeding. - Severe hypersensitivity reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hepatotoxicity: elevated liver enzymes or hepatitis. - Renal impairment: acute kidney injury or worsening chronic kidney disease. - Cardiovascular events: myocardial infarction or stroke.

When prescribing meloxicam, clinicians should consider several safety precautions to minimize risk. - Renal function: assess baseline kidney function and monitor periodically. - Cardiovascular risk: avoid in patients with recent myocardial infarction or uncontrolled hypertension. - Gastrointestinal history: use caution in individuals with prior ulcers or bleeding. - Hepatic status: monitor liver enzymes in patients with liver disease. - Concomitant NSAIDs or anticoagulants: increase risk of bleeding; evaluate necessity. - Store at ambient temperature: keep below 25 °C, in the original container, protected from moisture and light.

Meloxicam may interact with other medicines, altering efficacy or safety.

Major Interactions (Avoid): - Anticoagulants (e.g., warfarin): increased bleeding risk. - Selective COX‑2 inhibitors: additive cardiovascular toxicity. - Lithium: elevated serum lithium levels. - Methotrexate: enhanced methotrexate toxicity. - ACE inhibitors or ARBs: possible reduction in renal function.

Moderate Interactions (Monitor Closely): - Diuretics: may affect renal clearance of meloxicam. - SSRIs or SNRIs: modest increase in bleeding tendency. - Corticosteroids: heightened gastrointestinal ulcer risk. - Cyclosporine: potential for increased nephrotoxicity. - Oral hypoglycemics: may require dose adjustment.